Abstract
OBJECTIVE: To explore the correlation between α-ketoglutarate and the oxidative stress response in patients with coronary heart disease (CHD) and to analyze the prognosis of CHD patients receiving interventional treatment. METHODS: A total of 318 CHD patients admitted from September 2020 to September 2023 were selected and divided into a conservative medical treatment group (159 patients) and an interventional treatment group (159 patients) according to the treatment plan. The interventional treatment group was divided into an event group and a nonevent group according to whether the primary endpoint event occurred; another 59 patients with healthy physical examination results during the same period composed the control group. THE RESULTS: The serum TAC, SOD, CAT, and GSH levels in the conservative medical treatment group were lower than those in the control group (P < 0.05), and the serum MDA level was higher than that in the control group (P < 0.05). α-Ketoglutarate was correlated with oxidative stress indicators (TAC, SOD, CAT, and GSH) in patients with CHD (P < 0.05). A comparison of the α-ketoglutarate levels revealed that the control group > interventional treatment group > medical conservative treatment group (P < 0.05) and that the α-ketoglutarate level in the event group was lower than that in the nonevent group (P < 0.05). The ROC curve analysis results revealed that the area under the ROC curve (AUC) of α-ketoglutarate in the event group after interventional treatment was 702; the AUC of α-ketoglutarate in the no-event group was 802. CONCLUSION: α-Ketoglutarate is related to oxidative stress in patients with CHD. The lower the serum α-ketoglutarate level is, the greater the likelihood that adverse events will occur.